| mRNA |
piperlongumine:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0004 |
| mRNA |
ceranib-2 |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.003 |
| mRNA |
Gemcitabine |
gCSI |
pan-cancer |
AAC |
-0.16 |
0.008 |
| mRNA |
CCT036477 |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.01 |
| mRNA |
MST-312 |
CTRPv2 |
pan-cancer |
AAC |
0.094 |
0.01 |
| mRNA |
PL-DI |
CTRPv2 |
pan-cancer |
AAC |
0.082 |
0.01 |
| mRNA |
PD-0332991 |
CCLE |
pan-cancer |
AAC |
-0.13 |
0.02 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.085 |
0.02 |
| mRNA |
SB-225002 |
CTRPv2 |
pan-cancer |
AAC |
0.077 |
0.02 |
| mRNA |
PHA-665752 |
CCLE |
pan-cancer |
AAC |
-0.12 |
0.02 |